Business Description
Ocumension Therapeutics
ISIN : KYG674111011
Share Class Description:
HKSE:01477: Ordinary SharesTotal Employee Number:
552Compare
Compare
Traded in other countries / regions
01477.Hong KongOCUTF.USA5DG.Germany Index Membership
Hong Kong Stock Connect IPO Date
2020-07-10Description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.92 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -16.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.04 | |||||
Beneish M-Score | -1.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 58.7 | |||||
3-Year EBITDA Growth Rate | 70.1 | |||||
3-Year EPS without NRI Growth Rate | 31.9 | |||||
3-Year FCF Growth Rate | 17.8 | |||||
3-Year Book Growth Rate | 4.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 35.2 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.7 | |||||
9-Day RSI | 43.73 | |||||
14-Day RSI | 46.05 | |||||
3-1 Month Momentum % | -38.78 | |||||
6-1 Month Momentum % | -38.7 | |||||
12-1 Month Momentum % | -57.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.7 | |||||
Quick Ratio | 3.46 | |||||
Cash Ratio | 2.13 | |||||
Days Inventory | 47.85 | |||||
Days Sales Outstanding | 101.64 | |||||
Days Payable | 31.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | -2.76 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.91 | |||||
Operating Margin % | -19.36 | |||||
Net Margin % | -19.65 | |||||
EBITDA Margin % | -1.45 | |||||
FCF Margin % | -44.49 | |||||
OCF Margin % | -13.01 | |||||
ROE % | -4.32 | |||||
ROA % | -4.01 | |||||
ROIC % | -4.8 | |||||
3-Year ROIIC % | 17.53 | |||||
ROC (Joel Greenblatt) % | -26.77 | |||||
ROCE % | -4.13 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 109.35 | |||||
PS Ratio | 4.49 | |||||
PB Ratio | 0.99 | |||||
Price-to-Tangible-Book | 3.4 | |||||
EV-to-EBIT | -20.8 | |||||
EV-to-EBITDA | -276.12 | |||||
EV-to-Revenue | 4.02 | |||||
EV-to-FCF | -9.03 | |||||
Price-to-GF-Value | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 6.8 | |||||
| Price-to-Net-Cash | 26.47 | |||||
Earnings Yield (Greenblatt) % | -4.81 | |||||
FCF Yield % | -9.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ocumension Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 885.157 | ||
| EPS (TTM) (HK$) | -0.219 | ||
| Beta | 1.2772 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.27 | ||
| Volatility % | 29.94 | ||
| 14-Day RSI | 46.05 | ||
| 14-Day ATR (HK$) | 0.38247 | ||
| 20-Day SMA (HK$) | 5.389 | ||
| 12-1 Month Momentum % | -57.34 | ||
| 52-Week Range (HK$) | 4.04 - 12.23 | ||
| Shares Outstanding (Mil) | 803.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ocumension Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ocumension Therapeutics Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ocumension Therapeutics Frequently Asked Questions
What is Ocumension Therapeutics(HKSE:01477)'s stock price today?
The current price of HKSE:01477 is HK$5.03. The 52 week high of HKSE:01477 is HK$12.23 and 52 week low is HK$4.04.
When is next earnings date of Ocumension Therapeutics(HKSE:01477)?
The next earnings date of Ocumension Therapeutics(HKSE:01477) is .
Does Ocumension Therapeutics(HKSE:01477) pay dividends? If so, how much?
Ocumension Therapeutics(HKSE:01477) does not pay dividend.
Articles on Ocumension Therapeutics
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers